↓ Skip to main content

Human Pancreatic Cancer-Associated Stellate Cells Remain Activated after in vivo Chemoradiation

Overview of attention for article published in Frontiers in oncology, May 2014
Altmetric Badge

Mentioned by

twitter
1 X user

Readers on

mendeley
37 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Human Pancreatic Cancer-Associated Stellate Cells Remain Activated after in vivo Chemoradiation
Published in
Frontiers in oncology, May 2014
DOI 10.3389/fonc.2014.00102
Pubmed ID
Authors

M. Carla Cabrera, Estifanos Tilahun, Rebecca Nakles, Edgar S. Diaz-Cruz, Aline Charabaty, Simeng Suy, Patrick Jackson, Lisa Ley, Rebecca Slack, Reena Jha, Sean P. Collins, Nadim Haddad, Bhaskar V. S. Kallakury, Timm Schroeder, Michael J. Pishvaian, Priscilla A. Furth

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is characterized by an extensive fibrotic reaction or desmoplasia and complex involvement of the surrounding tumor microenvironment. Pancreatic stellate cells are a key mediator of the pancreatic matrix and they promote progression and invasion of pancreatic cancer by increasing cell proliferation and offering protection against therapeutic interventions. Our study utilizes human tumor-derived pancreatic stellate cells (HTPSCs) isolated from fine needle aspirates of pancreatic cancer tissue from patients with locally advanced, unresectable pancreatic adenocarcinoma before and after treatment with full-dose gemcitabine plus concurrent hypo-fractionated stereotactic radiosurgery. We show that HTPSCs survive in vivo chemotherapy and radiotherapy treatment and display a more activated phenotype post-therapy. These data support the idea that stellate cells play an essential role in supporting and promoting pancreatic cancer and further research is needed to develop novel treatments targeting the pancreatic tumor microenvironment.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 37 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Switzerland 1 3%
Unknown 36 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 8 22%
Student > Bachelor 5 14%
Student > Master 5 14%
Researcher 5 14%
Professor 3 8%
Other 7 19%
Unknown 4 11%
Readers by discipline Count As %
Medicine and Dentistry 13 35%
Biochemistry, Genetics and Molecular Biology 8 22%
Agricultural and Biological Sciences 5 14%
Social Sciences 2 5%
Immunology and Microbiology 1 3%
Other 3 8%
Unknown 5 14%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 May 2014.
All research outputs
#22,760,732
of 25,374,917 outputs
Outputs from Frontiers in oncology
#15,919
of 22,416 outputs
Outputs of similar age
#209,337
of 241,873 outputs
Outputs of similar age from Frontiers in oncology
#67
of 97 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 22,416 research outputs from this source. They receive a mean Attention Score of 3.0. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 241,873 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 97 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.